Molecular techniques for identification of new prognostic and predictive markers

Breast cancer is a heterogeneous disease, associated with a variety of pathological features and clinical behaviour. Traditional prognostic factors based on clinical and pathological variables are unable to fully capture this heterogeneity. High-throughput technologies (HTT), however, offer the opportunity to extensively improve current knowledge regarding the molecular basis of clinical and biological heterogeneity, thus leading to the possibility of developing improved prognostic and predictive markers. The impact of these new tools introduced by the 'omics' sciences is becoming relevant on daily clinical prac…